• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Turing Announces Shkreli Resignation, Appoints Interim CEO


December 21, 2015.

Turing Pharmaceuticals has announced the resignation of Martin Shkreli from the position of Chief Executive Officer and the appointment of Ron Tilles to the position of Interim CEO.

Tilles, who will continue to serve as Chairman of the Board of Directors, commented: "We wish to thank Martin for helping us build Turing Pharmaceuticals into the dynamic research focused company it is today, and wish him the best in his future endeavors."

Tilles has been Chairman of the Board of Directors of Turing Pharmaceuticals since the company launched late last year. He began his career at Merrill Lynch in 1985 and subsequently worked with several other securities firms.  

Related Videos